Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE
MWN-AI** Summary
Allurion Technologies, Inc. (NYSE: ALUR) has announced its intention to appeal a delisting notice from the New York Stock Exchange (NYSE) due to an inability to meet compliance requirements regarding stockholder equity and market capitalization. Specifically, Allurion failed to demonstrate compliance with Section 802.01B of the Listed Company Manual, which mandates maintaining at least $50 million in stockholders’ equity or total market capitalization over a 30-trading-day average.
The company has expressed confidence that its shares will continue trading on the NYSE during the appeal process. Dr. Shantanu Gaur, the CEO, emphasized that the recent FDA approval received on February 20, 2026, is a pivotal step in their strategy to regain compliance or transition to listing on the NYSE American. Allurion is actively working on restoring compliance through various measures, including negotiations with creditors and capital raising initiatives. Notably, they have reached an agreement with their largest creditor to exchange outstanding debt securities for preferred stock, reflecting a significant premium over the current trading price, subject to certain conditions.
Although Allurion is committed to rectifying the compliance issues and appealing the exchange's decision, it acknowledges the inherent risks and uncertainties involved. Such risks may impact the company's ability not only to regain compliance with the NYSE but also to pursue listings on other exchanges. The company has outlined various forward-looking statements regarding its future achievements, product commercializations, and market strategies, but it cautions against undue reliance on these projections given the competitive and regulatory challenges in the industry.
Overall, Allurion is poised to navigate the delisting challenge as it aims to stabilize its market presence through its ongoing initiatives.
MWN-AI** Analysis
Allurion Technologies, Inc. (NYSE: ALUR) recently made headlines due to the NYSE's notice of intent to delist the company, stemming from its failure to meet the exchange's required minimum thresholds for stockholders’ equity and market capitalization. The company's plan to appeal this decision comes on the heels of significant developments, including receiving FDA approval for its product, the Allurion Gastric Balloon System, which it believes will catalyze a path towards regaining compliance with NYSE listing standards.
Investors should remain cautious but hopeful. Allurion's proactive engagement with the NYSE and its announcement of an appeal suggest that the company is taking steps to address its compliance issues. Importantly, there’s an expectation that shares will continue trading on the NYSE throughout the appeal process. This is reassuring for existing shareholders, who may be wary of the implications of delisting.
The company’s strategy encompasses various financial maneuvers, including restructuring arrangements with its largest creditor to convert outstanding debt into preferable equity positions. This move could potentially alleviate some financial burdens and position Allurion favorably for future capital raising efforts.
However, the path ahead remains uncertain. While the FDA approval is a positive milestone, there are risks associated with the company’s ability to reinstate compliance or secure a listing on an alternative exchange if necessary. Investors should monitor developments closely, especially regarding any shifts in financial health or market conditions that may affect Allurion's operational framework.
In summary, while Allurion appears determined and is taking actionable steps towards compliance, potential investors should weigh the risks involved in the ongoing appeal and remain abreast of the company’s operational updates and market analytics before making any investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Company’s recent FDA approval catalyzes plan to regain compliance with listing requirements of NYSE or another exchange; shares of common stock expected to continue trading on NYSE during appeal process
Allurion Technologies, Inc. (the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, has received notice from the New York Stock Exchange (NYSE) that it intends to initiate delisting proceedings against Allurion after the Company was unable to demonstrate that it had regained compliance with Section 802.01B of the Listed Company Manual requiring listed companies to maintain either (i) at least $50 million in stockholders’ equity or (ii) at least $50 million in total market capitalization on a 30-trading day average basis. The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange (the “Committee”).
Allurion intends to appeal, and the Company expects its common stock to continue to trade on the NYSE during the appeal process.
“We have been in regular contact with the NYSE about our step-by-step plan to regain compliance with its listing standards or initiate listing on the NYSE American,” said Dr. Shantanu Gaur, Founder and Chief Executive Officer. “The first step in our plan was receiving FDA approval on February 20, 2026. We believe this approval will catalyze the remaining parts of our plan to regain compliance or relist, and we expect our common stock to remain trading on the NYSE while we execute this plan.”
The Company’s efforts to regain compliance with the continued listing requirements of the NYSE or gain compliance with the initial listing requirements of another exchange are ongoing and include discussions and negotiations with existing creditors and security holders, as well as capital raising efforts. In furtherance thereof, the Company has previously announced an agreement with its largest creditor to exchange all of its outstanding debt securities for shares of preferred stock at an exchange ratio representing a substantial premium to the Company’s current trading price, subject to certain conditions, and the completion of a warrant inducement transaction on February 24, 2026.
While the Company is working diligently to regain compliance and intends to appeal the NYSE staff determination, there is no guarantee that the Company will regain compliance with, and remain listed on, the NYSE, or be able to relist on another national exchange.
Forward-Looking Statements
This press release contains forward-looking statements that reflect Allurion’s beliefs and assumptions based on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terms, although not all forward-looking statements contain these words. Although Allurion believes it has a reasonable basis for each forward-looking statement contained in this release, these statements involve risks and uncertainties that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.
Forward-looking statements in this press release include, but are not limited to, statements regarding: our efforts to regain compliance with the NYSE continued listing standards or apply for an initial listing on another exchange; our ability to obtain capital through an equity financing or otherwise; our expectations relating to the use of the Allurion Gastric Balloon System (including in combination with GLP-1 therapies) to treat obesity, including with respect to its therapeutic benefits and the acceptance of Allurion’s products in the marketplace; our estimates regarding the number of patients using GLP-1 therapies; establishing a new standard for weight loss; pioneering in, and providing more patients and providers access to, metabolically healthy weight loss; and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to management.
Allurion cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward looking statements are subject to a number of risks and uncertainties, including, among others, general economic, political and business conditions; the ability of Allurion to obtain and maintain regulatory approval for, and successfully commercialize, the Allurion Gastric Balloon System, including the Allurion Smart Capsule; the timing of, and results from, Allurion’s clinical studies and trials, including with respect to the combination of GLP-1s with the Allurion Smart Capsule; the evolution of the markets in which Allurion competes, including the impact of GLP-1 drugs; the ability of Allurion to regain compliance with the continued listing standards of the New York Stock Exchange or qualify for an initial listing on another exchange; a changing regulatory landscape in the highly competitive industry in which Allurion competes; the impact of the imposition of current and potential tariffs and trade negotiations, and those factors discussed under the heading “Risk Factors” in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 27, 2025, and as amended on August 19, 2025, and updated from time to time by its other filings with the SEC, and its Quarterly Report on Form 10-Q filed with the SEC on November 17, 2025. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Allurion undertakes no obligation to update any forward-looking statements to reflect any new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events, other than as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260302557005/en/
Investor Contact
investors@allurion.com
FAQ**
How does Allurion Technologies Inc. (ALUR) plan to implement its strategy after the recent FDA approval to regain compliance with NYSE listing requirements?
What specific actions is Allurion Technologies Inc. (ALUR) taking to raise capital and negotiate with creditors amidst the ongoing appeal process against the NYSE delisting?
Given the uncertainty surrounding Allurion Technologies Inc. (ALUR) maintaining its NYSE listing, what alternatives does the company have for listing on another exchange?
How does Allurion Technologies Inc. (ALUR) assess the potential impact of recent market dynamics on its ability to successfully commercialize the Allurion Gastric Balloon System post-FDA approval?
**MWN-AI FAQ is based on asking OpenAI questions about Allurion Technologies Inc. (NYSE: ALUR).
NASDAQ: ALUR
ALUR Trading
3.58% G/L:
$0.7147 Last:
129,431 Volume:
$0.72 Open:
